NervGen Pharma Dirección

Dirección controles de criterios 1/4

El CEO de NervGen Pharma's es Mike Kelly , nombrado en Apr 2023, tiene una permanencia de 1.17 años. compensación anual total es CA$740.33K, compuesta por 72.9% salario y 27.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.21% de las acciones de la empresa, por valor de CA$331.10K. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 3.4 años, respectivamente.

Información clave

Mike Kelly

Chief Executive Officer (CEO)

CA$740.3k

Compensación total

Porcentaje del salario del CEO	72.9%
Permanencia del CEO	1.4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Kelly en comparación con los beneficios de NervGen Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CA$23m
Mar 31 2024	n/a	n/a	-CA$20m
Dec 31 2023	CA$740k	CA$540k	-CA$22m

Compensación vs. Mercado: La compensación total de Mike($USD543.12K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD176.00K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Mike con los resultados de la empresa.

CEO

Mike Kelly (58 yo)

1.4yrs

Permanencia

CA$740,330

Compensación

Mr. Michael Kelly, also known as Mike, is an Independent Director of ARS Pharmaceuticals, Inc. and joined in May 2019. He serves as Chief Executive Officer, President and Director of NervGen Pharma Corp. s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Kelly	CEO, President & Director	1.4yrs	CA$740.33k	0.21% CA$ 365.6k
William Radvak	Co-Founder & Advisor	no data	CA$60.00k	0% CA$ 0
Harold Punnett	Co-Founder & Independent Director	no data	sin datos	1.6% CA$ 2.9m
William Adams	CFO & Corporate Secretary	4.6yrs	CA$431.63k	0.22% CA$ 395.8k
Daniel Mikol	Chief Medical Officer	3.3yrs	CA$793.99k	sin datos
Brian McAlister	Co-Founder & Advisor	no data	sin datos	sin datos
Charles Olson	Senior Vice President of Technical Operations	less than a year	sin datos	sin datos
Elizabeth Eberhardt	Senior Vice President of Program Management	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NGEN no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Kelly	CEO, President & Director	1.4yrs	CA$740.33k	0.21% CA$ 365.6k
Harold Punnett	Co-Founder & Independent Director	7.7yrs	sin datos	1.6% CA$ 2.9m
Brian McAlister	Co-Founder & Advisor	no data	sin datos	sin datos
Glenn Ives	Chairman	3yrs	sin datos	0.083% CA$ 148.6k
Brian Bayley	Independent Director	6.3yrs	sin datos	0.57% CA$ 1.0m
Randall Kaye	Independent Director	3.9yrs	sin datos	0.014% CA$ 25.4k
Jeffrey Cummings	Member of Alzheimer's Disease Scientific Advisory Board	3.7yrs	sin datos	sin datos
Jerry Silver	Co-Inventor & Scientific Advisor	no data	sin datos	sin datos
George Perry	Member of Alzheimer's Disease Scientific Advisory Board	3.7yrs	sin datos	sin datos
Henrik Zetterberg	Member of Alzheimer's Disease Scientific Advisory Board	3.7yrs	sin datos	sin datos
Michael Davis	Advisor	3.9yrs	sin datos	sin datos
Bruce Lamb	Member of Alzheimer's Disease Scientific Advisory Board	3.7yrs	sin datos	sin datos

3.7yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NGEN se considera experimentada (3.4 años de antigüedad promedio).

NervGen Pharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

Independent Director exercised options to buy CA$272k worth of stock.

Recent updates

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad